CN1091006A - 用作降血糖药和治疗早老性痴呆症的化合物 - Google Patents

用作降血糖药和治疗早老性痴呆症的化合物 Download PDF

Info

Publication number
CN1091006A
CN1091006A CN93119081A CN93119081A CN1091006A CN 1091006 A CN1091006 A CN 1091006A CN 93119081 A CN93119081 A CN 93119081A CN 93119081 A CN93119081 A CN 93119081A CN 1091006 A CN1091006 A CN 1091006A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
compound
phenyl
thiazolidinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93119081A
Other languages
English (en)
Chinese (zh)
Inventor
D·C·亨顿
J·A·彭内塔
J·M·布-瓦列斯基
C·D·琼斯
W·N·肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1091006A publication Critical patent/CN1091006A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H2511/00—Dimensions; Position; Numbers; Identification; Occurrences
    • B65H2511/50—Occurence
    • B65H2511/51—Presence
    • B65H2511/512—Marks, e.g. invisible to the human eye; Patterns

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN93119081A 1992-09-10 1993-09-09 用作降血糖药和治疗早老性痴呆症的化合物 Pending CN1091006A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US943,353 1986-12-19
US94335392A 1992-09-10 1992-09-10

Publications (1)

Publication Number Publication Date
CN1091006A true CN1091006A (zh) 1994-08-24

Family

ID=25479507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93119081A Pending CN1091006A (zh) 1992-09-10 1993-09-09 用作降血糖药和治疗早老性痴呆症的化合物

Country Status (20)

Country Link
US (3) US5523314A (enExample)
EP (2) EP0587377A3 (enExample)
JP (1) JPH06192091A (enExample)
KR (1) KR940006590A (enExample)
CN (1) CN1091006A (enExample)
AU (1) AU676843B2 (enExample)
CA (1) CA2105598A1 (enExample)
CZ (1) CZ181493A3 (enExample)
FI (1) FI933946L (enExample)
HU (1) HUT70184A (enExample)
IL (1) IL106877A (enExample)
MX (1) MX9305444A (enExample)
MY (1) MY131443A (enExample)
NO (2) NO933198L (enExample)
NZ (1) NZ248573A (enExample)
PL (1) PL300335A1 (enExample)
RU (1) RU2131251C1 (enExample)
TW (1) TW274546B (enExample)
YU (1) YU59593A (enExample)
ZA (1) ZA936492B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
CN106008494A (zh) * 2016-05-31 2016-10-12 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
DE69530501D1 (de) * 1994-10-20 2003-05-28 Nippon Chemiphar Co Chinolinderivat
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
WO1996039194A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
AU726664B2 (en) * 1996-07-11 2000-11-16 Warner-Lambert Company Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6005142A (en) * 1996-09-03 1999-12-21 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
US6063799A (en) * 1996-09-03 2000-05-16 Eli Lilly And Company Alternate crystal form of Tazofelone
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
PT1014974E (pt) 1997-05-29 2004-12-31 Lundbeck & Co As H Tratamento da esquizofrenia e psicoses
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1117655A1 (en) * 1998-09-30 2001-07-25 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
AU6330999A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
CA2370316A1 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Rhodanine derivatives and their use in inhibiting and imaging amyloids
JP2003502320A (ja) * 1999-06-10 2003-01-21 ワーナー−ランバート・カンパニー アミロイドタンパク質凝集を阻害し、アミロイド沈着物を画像化する方法に使用するためのローダニン誘導体
US6372742B1 (en) 1999-07-01 2002-04-16 Geron Corporation Substituted indole compounds and methods of their use
EP1593677A3 (en) * 1999-08-31 2006-01-04 Incyte San Diego Incorporated Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
MXPA02002257A (es) * 1999-08-31 2002-09-30 Maxia Pharmaceuticals Inc Bencilideno-tiazolidinadionas y analogos y su uso en el tratamiento de la diabetes.
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6706766B2 (en) * 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ATE310733T1 (de) * 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
CA2405611A1 (en) * 2000-05-04 2001-11-08 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
GB0021421D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
IL157740A0 (en) 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
WO2002072543A2 (en) * 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
CA2340824A1 (en) * 2001-03-14 2002-09-14 Ibm Canada Limited-Ibm Canada Limitee Method and system for application behavior analysis
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
US7071218B2 (en) * 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
PL374718A1 (en) * 2002-07-10 2005-10-31 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US20060276520A1 (en) * 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
ATE411302T1 (de) 2002-11-22 2008-10-15 Smithkline Beecham Corp Thiazolidin-4-ones um hyak3 proteinen zu hemmen
WO2004066952A2 (en) * 2003-01-29 2004-08-12 Incyte Corporation Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050038098A1 (en) * 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
US20060106077A1 (en) * 2003-07-18 2006-05-18 Pintex Pharmaceuticals, Inc. Pin1-Modulating compounds and methods of use thereof
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DE102005022182A1 (de) * 2005-05-09 2006-11-16 Combinature Biopharm Ag Modulatoren der PDZ-Domäne
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
JP5315060B2 (ja) 2006-02-03 2013-10-16 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
JP5190957B2 (ja) 2006-04-28 2013-04-24 国立大学法人 鹿児島大学 アミロイドβ線維化阻害ペプチド
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
EP2217573A4 (en) * 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
KR20160127181A (ko) * 2008-08-12 2016-11-02 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
AU2010232923A1 (en) * 2009-04-03 2011-11-03 Medisyn Technologies, Inc. Compositions for treatment of Alzheimer's disease
BR112012015248B1 (pt) * 2009-12-23 2022-01-04 Jasco Pharmaceuticals, LLC Composto
EP2399612B1 (en) * 2009-12-25 2018-02-21 Canon Kabushiki Kaisha Composition for labeling tissues of central nervous system, method for labeling tissues of central nervous system, and screening method using the composition for labeling tissues of central nervous system
EP2665479B1 (en) 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
WO2013183718A1 (ja) * 2012-06-06 2013-12-12 国立大学法人京都大学 スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価
HK1214760A1 (zh) 2012-11-05 2016-08-05 Commissariat à l'énergie atomique et aux énergies alternatives 用於消除体内血癌干细胞以及用於防止血癌复发的抗癌试剂如酪氨酸激酶和stat5拮抗剂优选为噻唑烷二酮的组合
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN104557767B (zh) * 2015-01-14 2016-06-29 成都中医药大学 罗丹宁手性环己烷螺环化合物及其制备方法与用途
WO2021133037A1 (ko) * 2019-12-26 2021-07-01 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU173773A (enExample) *
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPS5728074A (en) * 1980-07-28 1982-02-15 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation, and inhibitor for aldose reducing enzyme consisting essentially of it
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
US4552891A (en) * 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
JPS6212776A (ja) * 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
GR862081B (en) * 1985-08-09 1986-12-24 Lilly Co Eli Di-t-butylphenol compounds
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
CA1325222C (en) * 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
KR870006897A (ko) * 1986-01-07 1987-08-13 모리오까 시게오 헤테로시클릭 화합물, 그의 제조 방법 및 이를 함유하는 제약 조성물
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
EP0316723B1 (en) * 1987-11-20 1992-09-30 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US4863923A (en) * 1988-07-01 1989-09-05 Eli Lilly And Company Method of inhibiting superoxide release
EP0391644B1 (en) * 1989-04-07 1996-06-19 Eli Lilly And Company Aryl-substituted rhodanine derivatives
JPH02300119A (ja) * 1989-05-11 1990-12-12 Kanegafuchi Chem Ind Co Ltd 過酸化脂質生成抑制剤
DE69024843T2 (de) * 1989-05-19 1996-05-30 Nisshin Flour Milling Co., Ltd., Tokio/Tokyo Rhodanin-Derivate und pharmazeutische Zusammensetzungen
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
DE4027038A1 (de) * 1990-08-27 1992-03-05 Wella Ag 3-amino-5-benzyliden-2-thioxo-thiazolidin-4- one, verfahren zu deren herstellung und diese enthaltendes kosmetisches mittel
EP0770644A1 (en) * 1991-02-15 1997-05-02 Mitsui Toatsu Chemicals, Incorporated Transparent impact-resistant molded articles
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US5320770A (en) * 1992-04-27 1994-06-14 Dow Corning Corporation Electrorheological (ER) fluid based on amino acid containing metal polyoxo-salts
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
US5236941A (en) * 1992-06-30 1993-08-17 American Home Products Corporation 5-(2-hydroxy-1-arylethylidene)- and 5-(2-oxo-1-arylethylidene)-2,4-thiazolidinediones and derivatives thereof
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
US5506745A (en) * 1994-08-05 1996-04-09 Xerox Corporation Hollow conformable charge roll

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
CN106008494A (zh) * 2016-05-31 2016-10-12 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用
CN106008494B (zh) * 2016-05-31 2019-08-27 广东工业大学 一种含4-氧代-2-硫代噻唑烷基衍生物及其制备方法与应用

Also Published As

Publication number Publication date
NO933198L (no) 1994-03-11
AU4621893A (en) 1994-03-17
FI933946A7 (fi) 1994-03-11
RU2131251C1 (ru) 1999-06-10
TW274546B (enExample) 1996-04-21
NO981911D0 (no) 1998-04-28
IL106877A0 (en) 1993-12-28
HU9302551D0 (en) 1993-11-29
NO933198D0 (no) 1993-09-08
EP0915090A1 (en) 1999-05-12
ZA936492B (en) 1995-03-02
HUT70184A (en) 1995-09-28
KR940006590A (ko) 1994-04-25
PL300335A1 (en) 1994-03-21
NZ248573A (en) 1996-02-27
CZ181493A3 (en) 1994-03-16
EP0587377A2 (en) 1994-03-16
JPH06192091A (ja) 1994-07-12
US5716975A (en) 1998-02-10
MX9305444A (es) 1994-05-31
YU59593A (sh) 1997-01-08
EP0587377A3 (en) 1994-09-21
AU676843B2 (en) 1997-03-27
IL106877A (en) 1998-03-10
US5661168A (en) 1997-08-26
MY131443A (en) 2007-08-30
FI933946L (fi) 1994-03-11
CA2105598A1 (en) 1994-03-11
NO981911L (no) 1994-03-11
FI933946A0 (fi) 1993-09-09
US5523314A (en) 1996-06-04

Similar Documents

Publication Publication Date Title
CN1091006A (zh) 用作降血糖药和治疗早老性痴呆症的化合物
CN1184215C (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
CN1098838C (zh) 被取代的N－(吲哚－2－羰基)－β－丙氨酰胺与作为抗糖尿病药的衍生物
CN1034864C (zh) 咪唑烷-4-酮和噻唑烷-4-酮的衍生物的制备方法
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1190434C (zh) 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1279617A (zh) 醛糖还原酶抑制剂和糖原磷酸化酶抑制剂的组合物
CN1032751C (zh) 噻唑烷化合物，其制备及其治疗用途
CN1157288A (zh) 苯并咪唑衍生物，其制备方法和其医疗用途
CN1161035A (zh) 降血脂1，4-苯并氮杂䓬-1，1-二氧化物
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
CN1543459A (zh) 具有唑基的喹啉衍生物和喹唑啉衍生物
CN1468211A (zh) 亚硝基二苯胺衍生物
CN1720049A (zh) 2－取代的4－杂芳基－嘧啶的治疗用途
CN1029846C (zh) 制备噻唑烷酮衍生物的方法
CN87105501A (zh) 新苯氧基乙酸衍生物及其制备方法和含有它作为活性成分的药物组成
CN1064273A (zh) 新的具有ngf生成促进活性的苯衍生物
CN1902185A (zh) 噻唑烷酮类化合物、其制备方法以及作为药物的应用
CN1612868A (zh) 哌嗪衍生物及其作为磷脂酶的用途
CN1254334A (zh) 新颖的对苯二甲酰胺衍生物
HK1047277A1 (zh) 吡嗪酮凝血酶抑制剂
CN1993367A (zh) 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
CN1839131A (zh) 吡咯烷甲腈类化合物及其作为dpp－iv抑制剂的应用
CN1106405A (zh) 用于调节多药抗性的三取代嘧啶并[5，4-d]嘧啶类，及含有该化合物的药物组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication